Literature DB >> 18490707

Cutting edge: soluble IL-6R is produced by IL-6R ectodomain shedding in activated CD4 T cells.

Eva M Briso1, Oliver Dienz, Mercedes Rincon.   

Abstract

IL-6 trans-signaling via the soluble IL-6R (sIL-6R) plays an important role in the progression of several autoimmune diseases and cancer by providing IL-6-responsiveness to cells lacking IL-6R. However, the potential sources of sIL-6R are less understood. In this study we show that sIL-6R is produced by both naive and memory CD4 T cells upon TCR activation. The production of sIL-6R by activated CD4 T cells is mediated by shedding of the membrane-bound IL-6R, and this process correlates with the expression of the metalloproteinase ADAM17 in these cells. In contrast to CD4 T cells, CD8 T cells do not express ADAM17 and their production of sIL-6R is negligible. Thus, during an immune response CD4 T cells are an important source of sIL-6R. Production of sIL-6R by autoreactive CD4 T cells may contribute to their role in the development of autoimmune disease by conferring IL-6-responsiveness to cells lacking IL-6R such as synoviocytes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18490707      PMCID: PMC2692633          DOI: 10.4049/jimmunol.180.11.7102

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130.

Authors:  Mari A Nowell; Peter J Richards; Sankichi Horiuchi; Naoki Yamamoto; Stefan Rose-John; Nicholas Topley; Anwen S Williams; Simon A Jones
Journal:  J Immunol       Date:  2003-09-15       Impact factor: 5.422

2.  Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells.

Authors:  Sabine Dominitzki; Massimo C Fantini; Clemens Neufert; Alexei Nikolaev; Peter R Galle; Jürgen Scheller; Giovanni Monteleone; Stefan Rose-John; Markus F Neurath; Christoph Becker
Journal:  J Immunol       Date:  2007-08-15       Impact factor: 5.422

3.  Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.

Authors:  Eva V Acosta-Rodriguez; Giorgio Napolitani; Antonio Lanzavecchia; Federica Sallusto
Journal:  Nat Immunol       Date:  2007-08-05       Impact factor: 25.606

4.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo.

Authors:  R Atreya; J Mudter; S Finotto; J Müllberg; T Jostock; S Wirtz; M Schütz; B Bartsch; M Holtmann; C Becker; D Strand; J Czaja; J F Schlaak; H A Lehr; F Autschbach; G Schürmann; N Nishimoto; K Yoshizaki; H Ito; T Kishimoto; P R Galle; S Rose-John; M F Neurath
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

5.  Non-cell autonomous expression of TNF-alpha-converting enzyme ADAM17 is required for normal lymphocyte development.

Authors:  Nianyu Li; Kelli Boyd; Peter J Dempsey; Dario A A Vignali
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

6.  Shedding of interleukin-6 receptor and tumor necrosis factor alpha. Contribution of the stalk sequence to the cleavage pattern of transmembrane proteins.

Authors:  K Althoff; P Reddy; N Voltz; S Rose-John; J Müllberg
Journal:  Eur J Biochem       Date:  2000-05

Review 7.  The soluble interleukin 6 receptor: mechanisms of production and implications in disease.

Authors:  S A Jones; S Horiuchi; N Topley; N Yamamoto; G M Fuller
Journal:  FASEB J       Date:  2001-01       Impact factor: 5.191

Review 8.  Interleukin-6 and its receptor: from bench to bedside.

Authors:  Jürgen Scheller; Stefan Rose-John
Journal:  Med Microbiol Immunol       Date:  2006-05-31       Impact factor: 3.402

9.  Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses.

Authors:  T Jostock; J Müllberg; S Ozbek; R Atreya; G Blinn; N Voltz; M Fischer; M F Neurath; S Rose-John
Journal:  Eur J Biochem       Date:  2001-01

10.  Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex.

Authors:  Martin J Boulanger; Dar-chone Chow; Elena E Brevnova; K Christopher Garcia
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

View more
  79 in total

Review 1.  Interleukin-6 in bone metastasis and cancer progression.

Authors:  Tasnim Ara; Yves A Declerck
Journal:  Eur J Cancer       Date:  2010-03-23       Impact factor: 9.162

Review 2.  Metalloproteinases and their natural inhibitors in inflammation and immunity.

Authors:  Rama Khokha; Aditya Murthy; Ashley Weiss
Journal:  Nat Rev Immunol       Date:  2013-09       Impact factor: 53.106

Review 3.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors:  Simon A Jones; Jürgen Scheller; Stefan Rose-John
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

Review 4.  ADAM-17: the enzyme that does it all.

Authors:  Monika Gooz
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-04       Impact factor: 8.250

Review 5.  Omega-3 fatty acids, lipid rafts, and T cell signaling.

Authors:  Tim Y Hou; David N McMurray; Robert S Chapkin
Journal:  Eur J Pharmacol       Date:  2015-05-20       Impact factor: 4.432

6.  A Common Variant of IL-6R is Associated with Elevated IL-6 Pathway Activity in Alzheimer's Disease Brains.

Authors:  Patrick C G Haddick; Jessica L Larson; Nisha Rathore; Tushar R Bhangale; Qui T Phung; Karpagam Srinivasan; David V Hansen; Jennie R Lill; Margaret A Pericak-Vance; Jonathan Haines; Lindsay A Farrer; John S Kauwe; Gerard D Schellenberg; Carlos Cruchaga; Alison M Goate; Timothy W Behrens; Ryan J Watts; Robert R Graham; Joshua S Kaminker; Marcel van der Brug
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

Review 7.  Interleukin-6: designing specific therapeutics for a complex cytokine.

Authors:  Christoph Garbers; Sylvia Heink; Thomas Korn; Stefan Rose-John
Journal:  Nat Rev Drug Discov       Date:  2018-05-04       Impact factor: 84.694

8.  miR-146a suppresses STAT3/VEGF pathways and reduces apoptosis through IL-6 signaling in primary human retinal microvascular endothelial cells in high glucose conditions.

Authors:  Eun-Ah Ye; Jena J Steinle
Journal:  Vision Res       Date:  2017-04-26       Impact factor: 1.886

9.  Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.

Authors:  Christian Hundhausen; Alena Roth; Elizabeth Whalen; Janice Chen; Anya Schneider; S Alice Long; Shan Wei; Rebecca Rawlings; MacKenzie Kinsman; Stephen P Evanko; Thomas N Wight; Carla J Greenbaum; Karen Cerosaletti; Jane H Buckner
Journal:  Sci Transl Med       Date:  2016-09-14       Impact factor: 17.956

10.  Green tea epigallocatechin-3-gallate modulates differentiation of naïve CD4⁺ T cells into specific lineage effector cells.

Authors:  Junpeng Wang; Munkyong Pae; Simin Nikbin Meydani; Dayong Wu
Journal:  J Mol Med (Berl)       Date:  2012-10-12       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.